ATE320804T1 - Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme - Google Patents

Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme

Info

Publication number
ATE320804T1
ATE320804T1 AT96941518T AT96941518T ATE320804T1 AT E320804 T1 ATE320804 T1 AT E320804T1 AT 96941518 T AT96941518 T AT 96941518T AT 96941518 T AT96941518 T AT 96941518T AT E320804 T1 ATE320804 T1 AT E320804T1
Authority
AT
Austria
Prior art keywords
schizophrenia
antagonists
negative
treatment
cognitive symptoms
Prior art date
Application number
AT96941518T
Other languages
English (en)
Inventor
Daniel C Javitt
Original Assignee
Daniel C Javitt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21731199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE320804(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daniel C Javitt filed Critical Daniel C Javitt
Application granted granted Critical
Publication of ATE320804T1 publication Critical patent/ATE320804T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT96941518T 1995-12-07 1996-12-05 Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme ATE320804T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US836195P 1995-12-07 1995-12-07

Publications (1)

Publication Number Publication Date
ATE320804T1 true ATE320804T1 (de) 2006-04-15

Family

ID=21731199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96941518T ATE320804T1 (de) 1995-12-07 1996-12-05 Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme

Country Status (10)

Country Link
US (3) US5854286A (de)
EP (1) EP0871440B1 (de)
JP (3) JP2000501707A (de)
AT (1) ATE320804T1 (de)
DE (1) DE69635959T2 (de)
DK (1) DK0871440T3 (de)
ES (1) ES2260773T3 (de)
IL (1) IL124536A (de)
PT (1) PT871440E (de)
WO (2) WO1997020553A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
DE1073432T1 (de) * 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
US6416975B1 (en) * 1998-11-12 2002-07-09 Gliatech, Inc. Human glycine transporter type 2
WO2000062812A1 (en) * 1999-04-20 2000-10-26 Advocare International Llc Nutritional composition for improved cognitive performance
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
SI1368336T1 (sl) 2001-02-16 2006-10-31 Allelix Neuroscience Inc S tiofenom substituirani aminski derivati kot inhibitorji glyt-1
US20020187544A1 (en) * 2001-04-05 2002-12-12 Wisconsin Alumni Research Foundation Uropathogenic E. coli D-serine detoxification operon
JP4299243B2 (ja) * 2002-07-04 2009-07-22 田辺三菱製薬株式会社 統合失調症の検査、診断方法
FR2843590B1 (fr) * 2002-08-14 2007-10-05 Prestwick Scient Capital Inc Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
DK2009000T3 (da) * 2003-01-16 2011-09-05 Acadia Pharm Inc Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
MXPA05011198A (es) 2003-04-30 2005-12-14 Lundbeck & Co As H Derivados de oxifenilo aromaticos y de sulfanilfenilo aromaticos.
AU2004266057A1 (en) * 2003-08-21 2005-03-03 H.Lundbeck A/S The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
WO2005053619A2 (en) * 2003-12-04 2005-06-16 The Research Foundation Of The City University Of New York Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
EP1781279A2 (de) * 2004-06-11 2007-05-09 Egon Tech Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
AU2005308538A1 (en) * 2004-08-09 2006-06-01 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders
EP1830833B1 (de) * 2004-12-16 2010-01-27 Janssen Pharmaceutica N.V. Kombination aus einem glycin-transporter (glyt1) hemmer und einem antipsychotikum zur behandlung von symptomen von schizophrenie und ihre herstellung und verwendung
US7531572B2 (en) * 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
CA2681506C (en) 2007-03-19 2016-05-24 Perry Peters Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2010053976A2 (en) * 2008-11-04 2010-05-14 Mclean Hospital Corporation Drug-enhanced neurofeedback
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
WO2012065102A2 (en) * 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
ES2890492T3 (es) 2015-07-20 2022-01-20 Acadia Pharm Inc Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3558311A1 (de) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose
EP3615028A1 (de) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin zur behandlung von impulskontrollstörungen
AU2018284335A1 (en) 2017-06-12 2020-01-30 Glytech Llc. Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists
EP3675827A1 (de) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulierungen von pimavanserin
CN111491629A (zh) 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
IL275968B2 (en) * 2018-01-10 2024-07-01 Xwpharma Ltd Prodrugs of ketamine, compositions and uses thereof
US20220087970A1 (en) * 2019-01-18 2022-03-24 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
CN114786689A (zh) * 2019-11-18 2022-07-22 雀巢产品有限公司 用于在脑健康中使用的谷胱甘肽增强的组合物和方法
WO2023018966A1 (en) 2021-08-13 2023-02-16 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
JPH07103018B2 (ja) * 1988-09-16 1995-11-08 武田薬品工業株式会社 精神分裂病治療剤
JP2757960B2 (ja) * 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5179085A (en) * 1989-03-15 1993-01-12 Warner-Lambert Company N-substituted α-amino acids and derivatives thereof having pharmaceutical activity
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
EP0614487A4 (de) 1991-11-12 1995-04-19 Synaptic Pharma Corp DNA, die für einen Glycin-Transporter kodiert und Anwendungen dafür.
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina

Also Published As

Publication number Publication date
WO1997020552A1 (en) 1997-06-12
EP0871440B1 (de) 2006-03-22
EP0871440A4 (de) 1999-01-20
JP2013056918A (ja) 2013-03-28
US5837730A (en) 1998-11-17
IL124536A0 (en) 1998-12-06
JP2009167205A (ja) 2009-07-30
WO1997020553A1 (en) 1997-06-12
DE69635959T2 (de) 2006-12-07
PT871440E (pt) 2006-07-31
EP0871440A1 (de) 1998-10-21
DK0871440T3 (da) 2006-07-10
US6162827A (en) 2000-12-19
JP5363152B2 (ja) 2013-12-11
US5854286A (en) 1998-12-29
DE69635959D1 (de) 2006-05-11
ES2260773T3 (es) 2006-11-01
IL124536A (en) 2001-03-19
JP2000501707A (ja) 2000-02-15

Similar Documents

Publication Publication Date Title
ATE320804T1 (de) Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
NO911624D0 (no) Farmasoeytiske forbindelser.
MX9803753A (es) Acidos alfa-iminohidroxamicos y -carboxilicos n-sustituidos ciclicos y heterociclicos.
DE3878866D1 (de) 3-indolpyruvsaeure-derivate und deren verwendung als arznemittel.
TR199902538T2 (xx) Yeni bile�imler.
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
DE69805672D1 (de) Verwendung von Rifaximin als Medikament zur Behandlung von durch Cryptosporidiose verursachten Diarrhoeen
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
NO307645B1 (no) Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE308616T1 (de) Rantes mutanten und deren therapeutische verwendungen
DE69305267D1 (de) Zusammensetzung zur Behandlung von Mastitis und Metritis
DE69412178D1 (de) Apparat zur Behandlung von Lagen
UA39179C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб
CA2239624A1 (en) Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
ES8501397A1 (es) "procedimiento para preparar derivados de quinazolina"
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0871440

Country of ref document: EP